SCHEMBL2275659

SCHEMBL2275659

O=C(Cl)c1cncc(-n2cccc2)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AOC2 O75106 2/20 0.39
ALK Q9UM73 1/20 0.38
POLB P06746 4/20 0.38
CHRNB2 P17787 3/20 0.37
CHRNA4 P43681 3/20 0.37
HCAR2 Q8TDS4 1/20 0.35
L3MBTL1 Q9Y468 2/20 0.35
CHRNB4 P30926 5/20 0.35
CHRNA3 P32297 5/20 0.35
ALDH1A1 P00352 2/20 0.34
KDM4E B2RXH2 1/20 0.34
HPGD P15428 1/20 0.34
MAPK1 P28482 1/20 0.34
HSD17B10 Q99714 1/20 0.34
SIRT2 Q8IXJ6 1/20 0.33
SIRT1 Q96EB6 1/20 0.33
SIRT3 Q9NTG7 1/20 0.33
CASP6 P55212 2/20 0.33
NPC1 O15118 1/20 0.33
DNMT1 P26358 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30835180 0.84 HCAR2 (0.48) AOC2ALKPOLBCHRNB2CHRNA4
SCHEMBL1423044 0.84 HCAR2 (0.48) AOC2ALKPOLBCHRNB2CHRNA4
SCHEMBL25614166 0.82 CHRNB2 (0.49) AOC2CHRNB2CHRNA4SIRT2SIRT1
SCHEMBL7825483 0.78 ATM (0.56) AOC2L3MBTL1ALDH1A1KDM4EHPGD
SCHEMBL2268149 0.76 HCAR2 (0.48) POLBHCAR2ALDH1A1KDM4E
SCHEMBL7826720 0.76 SLC9A1 (0.39) AOC2CHRNB2CHRNA4SIRT2SIRT1
SCHEMBL27767836 0.74 AOC2 (0.62) AOC2POLBL3MBTL1ALDH1A1KDM4E
SCHEMBL27716761 0.73 CHRNB4 (0.60) CHRNB2CHRNA4CHRNB4CHRNA3ALDH1A1
SCHEMBL28771359 0.73 EPHB3 (0.58) L3MBTL1CHRNB4CHRNA3ALDH1A1HPGD
SCHEMBL1275121 0.71 AOC2 (0.58) AOC2POLBALDH1A1HPGDCASP6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101094829-B novel anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO.,LTD. (JP) 2012-02-08 CN disclosed
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
CN-101094829-A Novel anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO LTD (JP) 2007-12-26 CN disclosed
EP-1820795-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-08-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP26, MMP11 AOC2 327/4885ALK 2071/4885POLB 3860/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.